# Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration

> **NCT04700423** · PHASE2,PHASE3 · COMPLETED · sponsor: **Jennifer Keiser** · enrollment: 536 (actual)

## Conditions studied

- Trichuriasis
- Ascariasis
- Hookworm Infections
- Helminthes; Infestation, Intestinal

## Interventions

- **DRUG:** moxidectin (8 mg) / albendazole (400 mg)
- **DRUG:** ivermectin (200 µg/kg) / albendazole (400 mg)
- **DRUG:** ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]
- **DRUG:** ivermectin (200 µg/kg)
- **DRUG:** moxidectin (8 mg)

## Key facts

- **NCT ID:** NCT04700423
- **Lead sponsor:** Jennifer Keiser
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-01
- **Primary completion:** 2021-08-18
- **Final completion:** 2021-09-22
- **Target enrollment:** 536 (ACTUAL)
- **Last updated:** 2024-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04700423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04700423, "Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04700423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*